Evaluation of proteinuria and albuminuria
proteinuria · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Quantification and characterisation of proteinuria to stratify CKD risk and detect glomerular disease. Albumin:creatinine ratio drives CKD risk classification; nephrotic-range proteinuria or active sediment prompts nephrology referral and possible biopsy.
Red flags
- Nephrotic-range proteinuria with oedema/hypoalbuminaemia
- Proteinuria with haematuria/red cell casts and rising creatinine
- Discordant heavy dipstick proteinuria with low albuminuria (light chains/myeloma)
- Rapidly rising ACR
- Proteinuria with systemic features (rash, arthralgia, haemoptysis)
Assessment
Differential diagnosis
- Glomerular proteinuria (diabetic, hypertensive, glomerulonephritis)
- Tubular proteinuria (tubulointerstitial disease)
- Overflow proteinuria (myeloma light chains)
- Orthostatic/functional proteinuria (benign)
- Transient proteinuria (fever, exercise, UTI)
- Nephrotic syndrome from primary/secondary GN
Investigations
- Urine ACR (preferred) and/or PCR on an early-morning sample
- Urinalysis/microscopy for haematuria, casts, active sediment
- Renal function and electrolytes
- Blood pressure, HbA1c, lipids
- Serum/urine electrophoresis and free light chains if overflow/myeloma suspected
- Renal ultrasound; immunological and viral screen if glomerular disease suspected
Management
- Confirm persistent proteinuria with a quantified early-morning ACR/PCR (not just dipstick), repeating after excluding transient causes (UTI, fever, exercise)
- Quantify severity: moderately increased (A2) vs severely increased (A3)/nephrotic-range
- Assess for glomerular disease via urinalysis (haematuria, casts) and clinical context
- Screen for overflow proteinuria with serum/urine electrophoresis and free light chains if dipstick-ACR discordant or age/risk fits myeloma
- Identify and treat secondary drivers: diabetes, hypertension, obesity
- Start an ACE inhibitor or ARB and uptitrate for proteinuric CKD, monitoring potassium and creatinine
- Add an SGLT2 inhibitor for significant albuminuria/diabetic kidney disease per thresholds
- Optimise blood pressure to a low target and reduce dietary sodium
- Refer to nephrology for nephrotic-range proteinuria, active sediment, rapidly rising ACR, or declining eGFR
- Consider renal biopsy (via nephrology) for unexplained significant glomerular proteinuria
- Monitor ACR, eGFR, BP and potassium at regular intervals
- Address cardiovascular risk, which rises with albuminuria
Drugs & doses
Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily (titrate to max tolerated)
Dapagliflozin 10 mg PO once daily (albuminuric/diabetic CKD)
Atorvastatin 20 mg PO once daily (cardiovascular risk)
Finerenone 10-20 mg PO daily (residual albuminuria in diabetic CKD, if K+/eGFR permit)
Disposition
Primary care/CKD clinic for most; nephrology referral for nephrotic-range proteinuria, active sediment or rapid rise. Haematology if myeloma suspected.
Complications & pitfalls
- Progressive CKD
- Nephrotic syndrome and its thrombotic/infective complications
- Cardiovascular events (albuminuria is an independent risk marker)
- Missed myeloma if overflow proteinuria overlooked
- AKI from aggressive RAAS blockade in volume depletion
Exam pearls
- ACR detects albumin (glomerular) better than dipstick; PCR captures total protein including light chains
- Dipstick heavy but ACR low? Think overflow proteinuria/light chains — send electrophoresis
- Albuminuria is both a kidney and cardiovascular risk marker
- Orthostatic proteinuria is benign — confirm with a split day/night collection in young patients
- RAAS blockade plus SGLT2 inhibition is the core of proteinuria reduction
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.